Skip to content

Explore the Clinical Application Value of Ciprofol in Painless Colonoscopy

Clinical Use of Ciprofol in Painless Colonoscopy: a Large Sample, Multicenter, Randomized, Double-blind, Parallel-controlled Clinical Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05294679
Enrollment
110
Registered
2022-03-24
Start date
2022-06-01
Completion date
2023-04-30
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction of Anaesthesia

Keywords

Propofol, Ciprofol

Brief summary

This study used propofol as a positive control, and adopted a large-sample, multi-center, randomized, double-blind, positive parallel controlled trial design to explore the clinical application value of ciprofol in painless colonoscopy.

Detailed description

Subjects were randomly assigned 1:1 to receive intravenous ciprofol or propofol 1 hour prior to diagnosis and treatment. A centralized random grouping method was used in this study. After screening subjects, the researchers in each test center will log in to the random system after being confirmed by the researchers of the center, fill in the screening information, obtain the random number information, and issue the corresponding study drugs according to the random number. Random shelter number was generated by SAS software, and was used as the total blind base pair drug number and imported into the centralized random grouping system. In this study, evaluation researchers and drug administration researchers were set up. The whole process of the experiment was blind not only to the subjects, but also to the evaluation researchers. Evaluation investigators and administration investigators were set up in this study. The administration investigators were only involved in the process of random grouping, drug dispensing and administration, and the other processes including informed consent of subjects, screening, evaluation of efficacy indicators and safety, and planned visits were all completed by the evaluation investigators.

Interventions

DRUGPropofol

All patients completed pre-anaesthesia assessment, signed informed consent, and completed vital signs on the day before surgery, with values as baseline vital signs. On the day of surgery, after routine preparation before colonoscopy (fasting for at least 6h and water restriction for at least 2h before surgery), venous access was established in the left hand. 0.5μg/kg fentanyl was administered intravenously after oxygen inhalation through a nasal catheter (4-6 L/min). About 3 minutes after fentanyl administration, sedation induction was performed with ciprofol or propofol immediately.

DRUGCiprofol

Ciprofol

Sponsors

Sichuan Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

In this study, evaluation researchers and drug administration researchers were set up. The whole process of the experiment was blind not only to the subjects, but also to the evaluation researchers.

Intervention model description

Participants were randomly assigned 1:1 to receive intravenous ciprofol or propofol 1 hour before the start of treatment.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients undergoing painless colonoscopy; 2. Patients aged from 18 to 80 years old, no gender limitation; 3, 18 \< BMI \< 30kg/m2 \[BMI = weight (kg)/ height (m) squared\] 4\. American Society of Anesthesiologists (ASA) grades ⅰ \ ⅲ

Exclusion criteria

1. Preoperative blood pressure \>160/100 mmHG or \< 80/50 mmHG. 2. Preoperative ecg suggested heart rate \<50 times/min; 3. Acute respiratory tract infection with no cured history within 2 weeks; 4. People with serious metabolic diseases such as heart, brain, lung, liver, kidney and diabetes; 5. Predict people who may have or have had difficult airway; 6. Patients with obvious electrolyte disorders such as hyperkalemia; 7. Long-term use of immunosuppressants such as hormones or history of adrenocortical inhibition; 8. People who are known to be allergic to emulsions and opioids; 9. Preoperative combined use of other sedative and analgesic drugs 10. Suspected abuse of narcotic analgesics or sedatives; 11, there are neuromuscular system diseases, mental diseases and other people do not cooperate with the communication;

Design outcomes

Primary

MeasureTime frameDescription
the incidence of hypotensionDay 1Perioperative hypotension was defined as systolic blood pressure below 90mmHg, diastolic blood pressure below 50mmHg, or systolic blood pressure below baseline

Secondary

MeasureTime frameDescription
Blood pressureDay 1Record the blood pressure at entering the room (T0) , after anesthesia administration (T1),at time points 2min after anesthesia administration (T2), 4min after anesthesia administration (T3), at the end of surgery (T4), 5min after surgery (T5), 10min after surgery (T6), and before leaving the chamber (T7)
Heart rateDay 1Record the heart rate at entering the room (T0) , after anesthesia administration (T1),at time points 2min after anesthesia administration (T2), 4min after anesthesia administration (T3), at the end of surgery (T4), 5min after surgery (T5), 10min after surgery (T6), and before leaving the chamber (T7)
Respiratory rateDay 1Record the respiratory rate at entering the room (T0) , after anesthesia administration (T1),at time points 2min after anesthesia administration (T2), 4min after anesthesia administration (T3), at the end of surgery (T4), 5min after surgery (T5), 10min after surgery (T6), and before leaving the chamber (T7)
the successful sedation timeDay 1When the Patients'MOAA/S was 0 as the successful sedation time
Steward wakefulness ScoreDay 1Minimum value =0, maximum value =6, the higher the score, the higher the degree of wakefulness
Directional force scoreDay 1Minimum value =0, maximum value =10, the higher the score, the higher the degree of directivity
Incidence of adverse eventsDay 1including injection pain, intraoperative muscle fibrillation, hypoxemia, body movement, and postoperative complications
Oxygen saturation(SpO2 %)Day 1Record the oxygen satuaition at entering the room (T0) , after anesthesia administration (T1),at time points 2min after anesthesia administration (T2), 4min after anesthesia administration (T3), at the end of surgery (T4), 5min after surgery (T5), 10min after surgery (T6), and before leaving the chamber (T7)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026